Metabolically Silent Diffuse Hepatic Involvement in Multiple Myeloma: An 18F-FDG-PET/CT Pitfall
PDF
Cite
Share
Request
Interesting Image
E-PUB
6 March 2026

Metabolically Silent Diffuse Hepatic Involvement in Multiple Myeloma: An 18F-FDG-PET/CT Pitfall

Mol Imaging Radionucl Ther. Published online 6 March 2026.
1. Bursa Uludağ University Faculty of Medicine, Department of Nuclear Medicine, Bursa, Türkiye
2. Recep Tayyip Erdoğan University Training and Research Hospital, Clinic of Nuclear Medicine, Rize, Türkiye
No information available.
No information available
Received Date: 11.12.2025
Accepted Date: 10.02.2026
E-Pub Date: 06.03.2026
PDF
Cite
Share
Request

Abstract

Diffuse hepatic involvement in multiple myeloma is rare and may present a diagnostic challenge 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT). We present the case of a 59-year-old man with a 3-year history of multiple myeloma who developed progressive hepatomegaly and perihepatic ascites. 18F-FDG PET/CT demonstrated marked diffuse liver enlargement without any focal or diffuse hepatic 18F-FDG uptake, while mild diffuse skeletal uptake suggested a globally 18F-FDG-low myeloma phenotype. Given the discordance between severe morphological findings and the absence of hepatic metabolic activity, a liver biopsy was performed, which revealed diffuse sinusoidal infiltration by CD138-positive, lambda-restricted plasma cells and excluded hepatic amyloidosis. Following systemic therapy, hepatomegaly and ascites regressed, while hepatic 18F-FDG uptake remained absent. Written informed consent for publication was obtained from the patient. This case highlights an important limitation of 18F-FDG PET/CT in detecting diffuse hepatic myeloma and emphasizes the need for multimodal diagnostic integration.

Keywords:
18F-FDG PET/CT, hepatic myeloma, diagnostic pitfall, multiple myeloma, hepatomegaly, liver biopsy

Ethics

Informed Consent: Written informed consent for publication was obtained from the patient.

Authorship Contributions

Surgical and Medical Practices: S.B., Concept: S.B., E.A.İ., Design: S.B., M.O., E.A.İ., Data Collection or Processing: S.B., E.A.İ., Analysis or Interpretation: S.B., E.A.İ., Literature Search: M.O., E.A.İ., Writing: S.B., M.O., E.A.İ.
Conflict of Interest: No conflicts of interest were declared by the authors.
Financial Disclosure: The authors declare that this study has received no financial support.

References

1
Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, Hillengass J, Engelhardt M, Usmani SZ, Vesole DH, San-Miguel J, Kumar SK, Richardson PG, Mikhael JR, da Costa FL, Dimopoulos MA, Zingaretti C, Abildgaard N, Goldschmidt H, Orlowski RZ, Chng WJ, Einsele H, Lonial S, Barlogie B, Anderson KC, Rajkumar SV, Durie BGM, Zamagni E. Role of 18 F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017;18:e206-e217.
2
Tirumani SH, Sakellis C, Jacene H, Shinagare AB, Munshi NC, Ramaiya NH, Van den Abbeele AD. Role of FDG-PET/CT in extramedullary multiple myeloma: correlation of FDG-PET/CT findings with clinical outcome. Clin Nucl Med. 2016;41:e7-e13.
3
Tirotta D, Lena C, Torre M, Muratori P. Hematologic focal hepatic lesions in the absence of liver cirrhosis: consider lymphoma and myeloma. Clin Res Hepatol Gastroenterol. 2026;50:102749.
4
Tomasian A, Sandrasegaran K, Elsayes KM, Shanbhogue A, Shaaban A, Menias CO. Hematologic malignancies of the liver: spectrum of disease. Radiographics. 2015;35:71-86.
5
Pu Z, Zhan L, Zha Y, Li Y, Qiu S, He Y, Yang Y, Feng Z, Zhu X. Hepatic involvement as an initial manifestation of multiple myeloma: a case report with atypical imaging features. Front Oncol. 2025;15:1640981.
6
Singh M, Singh H, Pham P, Rizvi B, Rao R. Extramedullary multiple myeloma with hepatic involvement. Cureus. 2021;13:e13515.
7
Abe Y, Ikeda S, Kitadate A, Narita K, Kobayashi H, Miura D, Takeuchi M, O’uchi E, O’uchi T, Matsue K. Low hexokinase-2 expression-associated false-negative 18 F-FDG PET/CT as a potential prognostic predictor in patients with multiple myeloma. Eur J Nucl Med Mol Imaging. 2019;46:1345-1350.
8
Rasche L, Angtuaco E, McDonald JE, Buros A, Stein C, Pawlyn C, Thanendrarajan S, Schinke C, Samant R, Yaccoby S, Walker BA, Epstein J, Zangari M, van Rhee F, Meissner T, Goldschmidt H, Hemminki K, Houlston R, Barlogie B, Davies FE, Morgan GJ, Weinhold N. Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood. 2017;130:30-34.
9
Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A, Tacchetti P, Buttignol S, Perrone G, Brioli A, Pantani L, Terragna C, Carobolante F, Baccarani M, Fanin R, Fanti S, Cavo M. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118:5989-5995.
10
Shekhawat AS, Singh B, Malhotra P, Watts A, Basher R, Kaur H, Hooda M, Radotra BD. Imaging CXCR4 receptors expression for staging multiple myeloma by using 68 Ga-pentixafor PET/CT: comparison with 18 F-FDG PET/CT. Br J Radiol. 2022;95:20211272.
11
Kaya G, Akin S, Buyukasik Y, Bozkurt MF, Tuncel M, Kiratli PO. PET in myeloma redefined: a comparative imaging study with FDG and fluorocholine PET/CT. Eur J Nucl Med Mol Imaging. 2026;53:2325-2336.
12
Chavoshi M, Mirshahvalad SA, Kohan A, Ortega C, Metser U, Farag A, Kridel R, Hodgson D, Bhella S, Kukreti V, Veit-Haibach P. CXCR4-targeted PET imaging in hematologic malignancies: a systematic review and meta-analysis. Clin Nucl Med. 2025;50:e7-e16.